[8-K] Champions Oncology, Inc. Reports Material Event

Rhea-AI Filing Summary

Jabil Inc. (JBL) has received a Form 144 filing from insider Andrew Priestley covering the proposed sale of 3,702 common shares—about 0.003 % of the company’s 107.3 million shares outstanding. The transaction, to be executed through UBS Financial Services, carries an estimated aggregate market value of $832,950 (≈ $225 per share) and is expected on or after 23 Jul 2025. The shares stem from restricted-stock units that vested on 20 Jul 2025.

The notice also lists two prior sales by Priestley within the last three months: 13,913 shares on 18 Jun 2025 for $2.83 million and 3,782 shares on 21 Jul 2025 for $0.85 million, bringing total recent dispositions to 17,695 shares valued at roughly $3.68 million. No operational or financial performance data for Jabil accompanies the filing; Form 144 serves solely as regulatory disclosure of intended insider transactions.

Positive

• None.

Negative

• Continued insider selling trend may raise modest concern about insider sentiment despite the small share count.

Insights

Financial Analyst

TL;DR: Small, routine insider sale (3,702 shares) adds to recent disposals; immaterial to float, sentiment modestly negative.

Materiality: At 0.003 % of outstanding shares, the proposed sale is quantitatively insignificant, suggesting minimal impact on supply-demand dynamics or valuation. However, it extends a pattern of insider selling—17,695 shares already sold for $3.68 million in the prior quarter—potentially signaling the insider’s preference to monetize recent RSU vesting.
Market reading: Investors often regard persistent insider sales as a mild bearish indicator, though magnitude and motivation (tax, diversification) are crucial context. Because no adverse company information is cited and the sale represents routine 10b5-1 activity, I classify the filing as neutral overall.

0000771856false00007718562025-07-232025-07-23

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 23, 2025

CHAMPIONS ONCOLOGY, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-11504

52-1401755

(State or Other Jurisdiction

(Commission File Number)

(IRS Employer

of Incorporation)

Identification No.)

1 University Plaza, Suite 307, Hackensack, New Jersey 07601

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (201) 808-8400

N/A

(Former Name or Former Address if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

INFORMATION TO BE INCLUDED IN THE REPORT

Item 2.02. Results of Operations and Financial Condition.

On July 23, 2025, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s audited financial results for its fiscal year ended April 30, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1.

The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits

The following exhibit is filed herewith:

Exhibit No.

99.1 Press Release dated July 23, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CHAMPIONS ONCOLOGY, INC.

(Registrant)

Date:

July 23, 2025

By:

/s/ Ronnie Morris

Ronnie Morris

Chief Executive Officer

FAQ

How many Jabil (JBL) shares does Andrew Priestley plan to sell?

3,702 common shares according to the Form 144 notice.

What is the estimated value of the proposed sale?

Approximately $832,950, or about $225 per share.

When is the sale expected to occur?

On or after 23 July 2025 as disclosed in the filing.

How many shares has Priestley sold in the past three months?

17,695 shares for gross proceeds of roughly $3.68 million.

What percentage of Jabil’s outstanding shares does 3,702 shares represent?

Roughly 0.003 % of the 107.3 million shares outstanding.

Which form is used to disclose the planned sale?

The insider filed a Form 144 under Rule 144 of the Securities Act.